NNVCNYSE

NANOVIRICIDES, INC.

Healthcare·Oncology·Phase 2·Shelton, CT, United States
OncologyInfectious Disease

NANOVIRICIDES, INC. (NNVC): 7 pipeline candidates · ~5 mo cash runway. Updated within the last hour.

6.8/10

BioSniper Score

4-factor signal · derived from public data

Cash Runway1.4

5.1 months

Financial Health9.8

D/E 0.12 · 0% dilution

Pipeline Maturity6.0

Lead: Phase 2

Pipeline Breadth10.0

7 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for NANOVIRICIDES, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$30.6M

Cash

$3.2M

Quarterly Burn

$1.9M

Runway

5.1 mo

Revenue

$0

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Nov 2026
Today~7 mo out
Catalyst within runway

Pipeline (7 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

46

Total value held

$1.9M

HolderSharesValue
vanguard capital management llc1,022,954$933K
geode capital management, llc225,381$206K
blackrock, inc.158,752$145K
renaissance technologies llc134,900$123K
susquehanna international group, llp99,031$90K
vanguard fiduciary trust co90,060$82K
state street corp54,206$49K
bridgeway capital management, llc36,039$33K
citadel advisors llc35,900$33K
xtx topco ltd35,432$32K

Showing top 10 of 46 institutional holders of NANOVIRICIDES, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Dr. Anil R. Diwan Ph.D.

Frequently asked questions

How many drug candidates are in NANOVIRICIDES, INC.'s pipeline?

NANOVIRICIDES, INC. (NNVC) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is NANOVIRICIDES, INC.'s lead drug candidate?

NANOVIRICIDES, INC.'s most advanced tracked candidate is nv-387 (Phase 2) for COVID infection, RSV infection, Influenza, Smallpox, MPox.

What is NANOVIRICIDES, INC.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, NANOVIRICIDES, INC. has approximately 5.1 months of cash runway.

What is NANOVIRICIDES, INC.'s market capitalization?

NANOVIRICIDES, INC.'s market capitalization is approximately $30.6M.

Who is the CEO of NANOVIRICIDES, INC.?

Dr. Anil R. Diwan Ph.D. is the chief executive officer of NANOVIRICIDES, INC. (NNVC).

Get the full picture on NANOVIRICIDES, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.